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A rare cause of neonatal hypocalcemia: malignant
infantile osteopetrosis
Abstract: Malignant infantile osteopetrosis (MIOP) is a rare inherited bone disease characterized
by reduced or dysregulated activity of osteoclasts, which results in generalized osteosclerosis. This
leads to abnormal bone marrow cavity formation and to the clinical signs and symptoms of bone
marrow failure and nerve compression. Symptoms related to early or late hypocalcemia may
appear as the first presentation of MIOP in a newborn. We present a 14-day-old boy with neonatal
hypocalcaemia due to MIOP.
Key Words: Malignant infantile osteopetrosis, neonatal hypocalcaemia

1

2

Department of Pediatrics,
Faculty of Medicine,
Düzce University,
Düzce - TURKEY
Department of Pediatric
Hematology,
Faculty of Medicine,
Gazi University,
Ankara - TURKEY

Neonatal hipokalseminin nadir bir nedeni: malign infantil
osteopetrozis
Özet: Malign infantil osteopetrozis (MİOP), osteokalst aktivitesinde azalma veya regülasyon
bozukluğu sonucunda yaygın osteoskleroza yol açan nadir bir herediter hastalıktır. Bu durum
anormal kemik kavitesi, bunun sonucu olarakta kemik iliği yetmezliği ve sinir basısına ait klinik
bulgularla kendini gösterir. MİOP ilk olarak erken veya geç neonatal hipokalsemi ile ilişkili
semptomlarla kendini gösterebilir. MİOP’a bağlı neonatal hipokalsemi görülen 14 günlük bir
olguyu sunduk.
Anahtar Sözcükler: Malign infantil osteopetrozis, neonatal hipokalsemi
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Malignant infantile osteopetrosis (MIOP) is a rare autosomal recessive
disorder characterized by presentation within the first few months of life, and
manifestations relating to an underlying defect in osteoclastic bone resorption.
In such a condition, abnormal osteoclast activity paired with normal bone
formation by osteoblasts leads to the development of densely sclerotic fragile
bones. Accumulation of sclerotic bone results in reduced marrow space and
narrowed osseous foramina. Major consequences include marrow failure
(pancytopenia), extramedullary hematopoiesis (hepatosplenomegaly), and nerve
entrapment (progressive blindness and hearing loss) (1-4). Other presentations
include failure to thrive and recurrent infections; excessive bruising, nasal
congestion, and an abnormal craniofacial appearance are less common
presentations (4). Osteoclasts are of hematopoietic origin; thus, hematopoietic
stem cell transplantation is an effective treatment (1).
Hypocalcemia is a rare condition in association with MIOP. Hypocalcemia
manifests in newborns as irritability, muscular twitching, jitteriness, tremors,
convulsions, poor feeding, vomiting, and lethargy. MIOP remains essentially
unrecognized by clinicians as a cause of neonatal hypocalcemia.
Herein we present a hypocalcemic neonate with MIOP.
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Case Report
A 14-day-old male newborn was admitted to our
hospital due to decreased activity and sucking. He
was born to a 20-year-old first-time mother and
weighed 3400 g. There was no history of parental
consanguinity. Physical examination revealed pale
skin, decreased activity, and hepatosplenomegaly;
the liver was 4 cm below and the spleen was 5 cm
below the costal margin. Pale optic nerve heads were
observed with funduscopic examination. Laboratory
findings
demonstrated
thrombocytopenia
(93,000/μl), low hemoglobin level (11.4 g/dl), and
normal leukocyte count (7000/μl). Serum TORCH
IgM titers were negative. Biochemical analysis
revealed that aspartate aminotransferase (AST),
alanine aminotransferase (ALT), total calcium,
phosphorus, alkaline phosphatase, magnesium, 25hydroxy vitamin D, and parathormone levels were
114 U/l (15-55 U/l), 36 U/l (5-45 U/l), 6.8 mg/dl

Figure 1. Frontal radiograph shows the appearance of “space alien”
face.
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(8.8-10.8 mg/dl), 5 mg/dl (3.8-6.5 mg/dl), 900 U/l
(145-420 U/l), 1.9 mg/dl (1.6-2.6 mg/dl), 11.2 ng/ml
(1.9-33.4 ng/ml), and 435 pg/ml (9-65 pg/ml),
respectively. Moderate bilateral hearing loss was
noted with brain stem evoked response audiometry
(BERA). Visual evoked potential (VEP) testing
revealed
low
amplitude.
Whole-body
roentgenogram
investigation
demonstrated
uniformly dense, homogeneous, and sclerotic bone,
with the absence of corticomedular junctions
(Figure 1 and 2). The mother’s laboratory data
revealed a phosphorus level of 3.9 mg/dl (2.7-4.7
mg/dl) and total calcium level of 9.4 mg/dl (8.4-10.2
mg/dl).
Hypocalcemia was treated with infusion of
calcium gluconate (100 mg/kg IV). Because neonatal
sepsis was suspected, empiric antibiotics were given,
which included ampicillin and amikacin sulfate.
Serum calcium level increased to 9.2 mg/dl and an

Figure 2. Typical osteopetrosis increased bone density and loss of
normal corticomedular differentiation.
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improvement in clinical condition was observed 2
days following the initiation of treatment. The
patient was diagnosed with MIOP due to anemia
and thrombocytopenia, which resulted in bone
marrow failure, hepatosplenomegaly caused by
extramedullary hematopoiesis, optic atrophy,
hearing loss, and the accompanying radiological
signs. The patient was referred to another hospital
for bone marrow transplantation (BMT).
Discussion
The primary underlying defect in all types of
osteopetrosis is failure of the osteoclasts to reabsorb
bone. Osteoclasts can tightly attach to the bone
matrix via integrin receptors to form a sealing zone,
within which a sequestered compartment is
acidified. Acidification promotes solubilization of
the bone mineral in the sealing zone, and various
proteases—most notably cathepsin K—catalyze
degradation of the matrix proteins. Additionally,
actively resorbing osteoclasts release oxygen-derived
radicals, in particular superoxides, which probably
contribute to degradation of the bone matrix (5-7).
The 3 mutations that have been linked to
osteopetrosis cause defects in the acidification of
bone. The most common of these, observed in 50%60% of patients, results in defects in the A3 subunit
of the osteoclast vacuolar H+-ATPase proton pump.
The second most clinically significant mutation
affects CLCN7, a gene encoding an osteoclastspecific chloride channel. These mutations occur in
10%-15% of patients with severe autosomal recessive
osteopetrosis. Carbonic anhydrase II dysfunction is
a feature of autosomal recessive osteopetrosis, but
only accounts for a small proportion of patients with
osteopetrosis (8).
Patients may present with growth retardation,
macrocephaly, frontal bossing, delayed dental
development,
anemia,
thrombocytopenia,
hepatosplenomegaly, leukopenia, or hypocalcemic
convulsions. MIOP is generally diagnosed during
the first year of life, based on sclerosis in the bones
and obliteration of the bone marrow. This form of
the disease progresses quite rapidly, and patients
usually die during the first decade of life (9). The
presented case also had hepatosplenomegaly,
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anemia, thrombocytopenia, and hypocalcemia at
age 14 days.
Disturbances of calcium homoeostasis have been
well described in MIOP. The first description may
have been provided by Avery et al., who described a
baby born with osteopetrosis in 1956 that was a “bit
twitchy” at 6 days of age (10). Srinivasan et al.
reported symptomatic hypocalcemia that developed
in the first month of life in 8 infants from 6 different
families (11). Defective calcium metabolism was
observed in several other cases of MIOP (4). Our
patient’s serum calcium level was low. It was
reported that patients with osteopetrosis may suffer
from defective bone demineralization despite
sufficient calcium and phosphorus content in their
bodies, and therefore rickets may develop in these
patients. This condition, which is different than
osteopetrosis, has been referred to as
osteopetrorickets in the literature (12-14).
Parathormone and alkaline phosphatase levels were
high in our patient. Increased alkaline phosphatase
is a sign of defective bone mineralization, whereas a
high parathormone level is caused by low serum
calcium due to disturbed bone resorption by
defective osteoclasts. No radiological sign
supporting rickets was observed in our patient.
In MIOP, hearing loss and blindness commonly
occur due to the pressure exerted on cranial nerves
by sclerotic bony structures (15). In the presented
case, VEP evaluation revealed bilateral vision loss,
and moderate hearing loss was detected bilaterally
with BERA testing.
The most effective treatment for MIOP is
allogeneic BMT (1,16). When BMT cannot be
performed, corticosteroids, high-dose calcitriol,
erythropoietin, and interferon-gamma are among
the suggested supportive treatments. High-dose
steroid use has been reported to decrease bone
mineral density, whereas it decreases transfusion
demand at lower doses. High-dose calcitriol
stimulates the bone-resorptive function of
osteoclasts, while interferon-gamma slows the
process by enhancing bone resorption (17-19).
Among patients not transplanted, only 30% have
been reported to survive until 6 years of age.
Irreversible neurological signs appear as early as
459
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infancy. When hematological defects emerge during
the first 3 months of life, the prognosis is quite poor
(4,20).
MIOP has an extremely poor prognosis unless
treated early with hematopoietic stem cell
transplantation (4). It remains essentially
unrecognized as a cause of neonatal hypocalcemia,
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and often results in diagnostic confusion and delay.
Early diagnosis is important in the context of
curative BMT, for which preservation of sight
depends upon early medical intervention. MIOP
should be considered in the differential diagnosis of
idiopathic neonatal hypocalcemia.
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